Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

INDUSTRY × Thrombocythemia, Essential × imetelstat × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Recurrence 4 Myelodysplastic Syndromes 3 Primary Myelofibrosis 2 Neoplasms, Plasma Cell 2 Myeloproliferative Disorders 2 Multiple Myeloma 2 Thrombocytosis 1 Thrombocythemia, Essential 1 Polycythemia Vera 1 Polycythemia 1 Lung Neoplasms 1 Leukemia, Myeloid, Acute 1 Carcinoma, Non-Small-Cell Lung 1 Breast Neoplasms 1

Interventions

ruxolitinib 7 givinostat hydrochloride 3 givinostat 3 anagrelide 3 11-(2-pyrrolidin-1-ylethoxy)-14,19-dioxa-5,7,26-triazatetracyclo(19.3.1.1(2,6).1(8,12))heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-decaene 3 bomedemstat 2 LY2784544 2 spartalizumab 1 sonidegib 1 sabatolimab 1 navitoclax 1 lestaurtinib 1 imetelstat 1 ON 01910 1 NIS-793 1 N-(cyanomethyl)-4-(2-((4-(4-morpholinyl)phenyl)amino)-4-pyrimidinyl)benzamide 1 N-((5-bromo-2-thienyl)sulfonyl)-2,4-dichlorobenzamide 1 INCB057643 1 Fentanyl 1 Diagnosis 1 Decitabine 1 Celecoxib 1 CPI-0610 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT01243073 2016-01-26

ET/PV

Geron Corporation

Phase 2 Completed

Polycythemia Vera, Thrombocythemia, Essential

Data powered by HemOnc (CC BY 4.0) Colophon ⚡